Previous 10 | Next 10 |
BERKELEY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of c...
AbbVie (NYSE: ABBV ) has acquired Kirkland, WA-based Mavupharma , a privately held biopharma outfit developing cancer treatments based on the STING (STimulator on INterferon Genes) signaling pathway that plays a key role in the generation of an immune response to tumors. Financial te...
The following slide deck was published by Aduro BioTech, Inc. in conjunction with this Read more ...
Aduro Biotech ( ADRO -42.2% ) slumps on a 4x surge in volume in response to data presented at ASCO on STING candidate ADU-S100. More news on: Aduro BioTech, Inc., Novartis AG, Synlogic, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: Genocea Biosciences (NASDAQ: GNCA ) +45% . Mirati Therapeutics (NASDAQ: MRTX ) +34% . Cypress Semiconductor (NASDAQ: CY ) +25% . ARCA biopharma (NASDAQ: ABIO ) +23% . Centrus Energy (NYSEMKT: LEU ) +18% . Spirit MTA REIT (NYSE: SMTA ) +18% . El Paso Electric (NYSE: EE ...
ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-treated melanoma As of the April 5, 2019 data cut-off, five patients treated in the weekly dosing schedule...
Aduro BioTech (NASDAQ: ADRO ) slips 7% premarket on light volume on the heels of its announcement that will not proceed with the Phase 2 part of its Phase 1/2 clinical trial evaluating APRIL pathway candidate BION-1301 in multiple myeloma due to the "emergence of transforma...
BERKELEY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of ca...
First healthy volunteer cohort cleared in Phase 1 first-in-human study of BION-1301 for the treatment of IgA nephropathy (IgAN); initial data in healthy volunteers expected in H1 2020 and IgAN patients in H2 2020 Results from the dose escalation portion of the Phase 1/2 study in...
Peloton Therapeutics, Inc. ( PLTX ) is at an advanced stage of development, which will please many investors. The company expects to start patient enrollment for its Phase 3 clinical trial in the second half of 2019. Additionally, three years ago, competitors were valued at $250-500 million in...
News, Short Squeeze, Breakout and More Instantly...
Aduro Biotech Inc. Company Name:
ADRO Stock Symbol:
NASDAQ Market:
The 15th Annual Global CSR & ESG Awards Honours 2023 Winners DA NANG, VIETNAM, Aug 30, 2023 - (ACN Newswire) - The 15th Annual Global CSR & ESG Summit & Awards ended on a high note before a full house in Da Nang, Vietnam, on August 28. Organized at the Novotel Danang Pre...
Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therap...
One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (ST...